Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 15, Issue 7, 2013, Pages 668-673

  White, W B ^a   Pratley, R ^b   Fleck, P ^c   Munsaka, M ^c   Hisada, M ^c   Wilson, C ^c   Menon, V ^d  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b FLORIDA HOSPITAL   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiovascular disease; DPP IV inhibitor; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLIPIZIDE; HYPOCHOLESTEROLEMIC AGENT; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 84878939138     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12093     Document Type: Article

References (24)

1. Meigs JB. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta Diabetol 2003; 40(Suppl. 2): S358-361.
2. Centers for Disease Control and Prevention (CDC). National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2008. Available from URL: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed 16 February 2009.
3. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841.
4. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828.
5. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
6. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008; 359: 1092-1095.
7. Diabetes Mellitus. Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Available from URL: http://www.gpo.gov/fdsys/pkg/FR-2008-12-19/html/E8-30086.htm. Accessed 12 December 2012.
8. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663-1670.
9. Ghatak SB, Patel DS, Shanker N, Srivstava A, Deshpanda SS, Panchal SJ. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. Curr Diabetes Rev 2010; 6: 410-421.
10. Cox DR. Regression models and life-tables. J Royal Stat Soc 1972; 34: 187-220.
11. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vasc Pharmacol 2011; 55: 10-16.
12. Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet 2012; 380: 475-483.
13. Davidson MH. Cardiovascular effects of glucagon like peptide-1 agonists. Am J Cardiol 2011; 108(Suppl): 33B-41B.
14. Peskin BR, Shcheprov AV, Boye KS, Bruce S, Maggs DG, Gaebler JA. Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist versus traditional therapies for type 2 diabetes: a simulation analysis. Diabetes Obes Metab 2011; 13: 921-927.
15. Brown NJ. Cardiovascular effects of anti-diabetic agents: focus on blood pressure effects of incretin-based therapies. J Am Soc Hypertens 2012; 6: 163-168.
16. Eliasson B, Moller-Goede D, Eeg-Olofsson K et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomized double-blind placebo-controlled study. Diabetologia 2012; 55: 915-925.
17. White WB, Bakris GL, Bergenstal RM et al. Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome. Am Heart J 2011; 162: 620-626.
18. Pratley RE, Reusch J, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009; 25: 2361-2371.
19. DeFronzo R, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315-2317.
20. Pratley RE, Kipnes MS, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to glyburide therapy in patients with type 2 diabetes inadequately controlled on glyburide monotherapy. Diabetes Obes Metab 2009; 11: 167-176.
21. Nauck M, Ellis G, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63: 46-55.
22. Rosenstock J, Rendell M, Gross J, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11: 1145-1152.
23. Rosenstock JR, Inzucchi S, Seufert J, Fleck P, Wilson C, Mekki Q. Efficacy and tolerability of initial combination therapy with alogliptin and pioglitazone in patients with type 2 diabetes. Diabetes Care 2010; 33: 2406-2408.
24. Bosi E, Ellis G, Wilson C, Fleck P. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab 2011; 13: 1088-1096.